论文部分内容阅读
目的:观察鼻咽癌患者治疗前后恶性肿瘤相关物质群(TSGF)与EB病毒VCA-IgA抗体的水平和疗效的关系。方法:联合检测58例鼻咽癌患者在治疗前后TSGF水平与VCA-IgA抗体滴度的变化。结果:58例鼻咽癌患者治疗后TSGF水平与VCA-IgA抗体滴度比治疗前下降(P<0.05)。结论:动态监测TSGF和VCA-IgA抗体对于评价鼻咽癌患者的治疗效果有重要临床意义。
OBJECTIVE: To observe the relationship between the levels of the antibody against Epstein-Barr virus (VCA-IgA) and the efficacy of TSGF in patients with nasopharyngeal carcinoma before and after treatment. Methods: The changes of TSGF level and VCA-IgA antibody titers in 58 nasopharyngeal carcinoma patients before and after treatment were detected. Results: The TSGF level and the VCA-IgA antibody titer in 58 NPC patients were lower than those before treatment (P <0.05). Conclusion: Dynamic monitoring of TSGF and VCA-IgA antibodies has important clinical value in the evaluation of the therapeutic effect of patients with nasopharyngeal carcinoma.